Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunoglobulin (IgG) with recombinant human hyaluronidase - Takeda

Next Previous
Drug Profile

Immunoglobulin (IgG) with recombinant human hyaluronidase - Takeda

Alternative Names: 10% HyQ; 20% Solution with Recombinant Human Hyaluronidase; HyQvia; IGI 10% with rHuPH20; Immune Globulin Subcutaneous (Human); SCIG 20%; TAK 771; TAK-881

Latest Information Update: 07 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter International
  • Developer Takeda
  • Class Hydrolases; Immunoglobulins; Immunotherapies
  • Mechanism of Action Immunoglobulin G replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunological disorders; Toxic epidermal necrolysis; Stevens-Johnson syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Immunodeficiency disorders
  • Registered Multifocal motor neuropathy

Most Recent Events

  • 29 May 2026 Takeda completes a phase III trial in Chronic inflammatory demyelinating polyradiculoneuropathy in Japan (IV) (NCT05084053)
  • 20 Jan 2026 Takeda completes the phase II/III trial in Immunodeficiency disorders (In adolescents, In children, In the elderly, In adults) in USA, Czech Republic, Denmark, Germany, Netherlands, Poland, Slovakia and Spain (SC, Infusion) (NCT05755035)
  • 12 Dec 2025 Phase-III clinical trials in Immunodeficiency disorders (In children, In adolescents) in Canada (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top